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Summary
SEURAT-1 is a European public-private research consortium that is working towards animal-free testing of chemical 
compounds and the highest level of consumer protection. A research strategy was formulated based on the guiding 
principle to adopt a toxicological mode-of-action framework to describe how any substance may adversely affect human 
health. The proof of the initiative will be in demonstrating the applicability of the concepts on which SEURAT-1 is built 
on three levels: (i) Theoretical prototypes for adverse outcome pathways are formulated based on knowledge already 
available in the scientific literature on investigating the toxicological modes-of-action leading to adverse outcomes 
(addressing mainly liver toxicity); (ii) adverse outcome pathway descriptions are used as a guide for the formulation of 
case studies to further elucidate the theoretical model and to develop integrated testing strategies for the prediction of 
certain toxicological effects (i.e., those related to the adverse outcome pathway descriptions); (iii) further case studies 
target the application of knowledge gained within SEURAT-1 in the context of safety assessment. The ultimate goal would 
be to perform ab initio predictions based on a complete understanding of toxicological mechanisms. In the near-term, 
it is more realistic that data from innovative testing methods will support read-across arguments. Both scenarios are 
addressed with case studies for improved safety assessment. A conceptual framework for a rational integrated assessment 
strategy emerged from designing the case studies and is discussed in the context of international developments focusing 
on alternative approaches for evaluating chemicals using the new 21st century tools for toxicity testing.
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The full ban on animal testing for cosmetic products within the 
European Union came into force on 11 March 2013, despite the 
lack of validated alternative methods for reproductive toxicity 
(including teratogenicity), carcinogenicity, toxicokinetics and 
repeated dose systemic toxicity. Independent expert panels of 
scientists concluded that they could not even estimate the time 
required to establish alternative methods for the full replace-
ment of animal testing in the fields of repeated dose systemic 
toxicity, carcinogenicity and reproductive toxicity (Adler et al., 
2011; Hartung et al., 2011). Consequently, roadmaps for future 
research aiming at the development of alternative non-animal 
testing methods were formulated; these roadmaps highlighted 
the current state of research as well as knowledge gaps to be ad-
dressed in ongoing and upcoming research programs (Basketter 
et al., 2012). These roadmaps, and the call for proposals under 
the Health Theme of the 7th European Framework Programme 
“Towards the Replacement of in vivo Repeated Dose Systemic 
Toxicity Testing”, led to the creation of SEURAT-1 in 2011. 
This major European research consortium was established to 
develop the science needed to evaluate the safety of chemicals 
for repeated exposure in humans without using animals. The re-
search initiative is co-financed through a new model of public-
private partnership by the European Commission’s FP7 Health 
Programme and Cosmetics Europe.
SEURAT-1 is inspired by the fundamental considerations 
published in the report of the U.S. National Research Council 
(NRC) entitled “Toxicity Testing in the 21st century: A Vision 
and a Strategy” (NRC, 2007a) and the European Partnership for 
Alternatives to Animal Testing (EPAA) report “New Perspec-
tives on Safety” (EPAA, 2008), as well as numerous publica-
tions highlighting the consequences for future research (e.g., 
Andersen et al., 2011), the demands for the development of new 
testing approaches (Hartung et al., 2013a) and their implemen-
tation into safety assessment procedures (Krewski et al., 2011). 
No matter whether the new field of research is named predictive 
toxicology (NRC, 2007b) or systems toxicology (Hartung et al., 
2013b; Sturla et al., 2014), all these activities aim to use the 
mechanistic understanding of toxicological effects for the devel-
opment of innovative testing methods and, ultimately, improved 
safety assessment. SEURAT-1 shares these perspectives. 
The acronym “SEURAT” indicates the long-term goal of 
the initiative – Safety Evaluation Ultimately Replacing Ani-
mal Testing. The first execution phase, named SEURAT-1, was 
launched in January 2011 and focuses on the replacement of 
repeated dose systemic toxicity testing on animals. SEURAT-1 
is intended to be the first step towards the specific goal of ad-
dressing the global, long-term strategic target of replacing 
animal testing in safety assessments. It comprises a cluster 
of five complementary research projects combining expertise 
in: (i) stem cell differentiation and cell culturing for provid-
ing human-based, organ-specific target cells for toxicity test-
ing (SCR&Tox); (ii) the identification of new biomarkers for 
repeated dose toxicity (DETECTIVE); (iii) the development of 
organ-simulating devices mimicking the complex structure and 
Fig. 1: Building blocks of SEURAT-1 (themes, project logos and respective homepages)
these were established based on the call for proposals under the Health theme of the 7th european Framework Programme “towards 
the Replacement of in vivo Repeated Dose Systemic toxicity testing.”
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function of the human liver (HeMiBio); (iv) the development 
of systems biological tools for characterizing long-term toxic 
effects in organotypic human cell cultures (NOTOX); and (v) 
the development of integrated computational tools to predict 
long-term effects of chronic exposure to chemicals in humans 
(COSMOS). These research projects are accompanied by a data 
handling and servicing project (ToxBank) and a coordination 
action project (COACH). Each of the research projects has its 
own defined research agenda, which can be found on the re-
spective homepages, as indicated in Figure 1. 
Overall, the aim of SEURAT-1 is to provide a blueprint for 
future implementation of mechanism-based, integrated toxicity 
testing strategies into modern safety assessment approaches. For 
this, we outline first the key elements of the SEURAT research 
strategy and then describe how the theory is being brought in-
to practice within SEURAT-1 through the formulation of case 
studies using mode-of-action descriptions as starting points for 
the development of in silico and in vitro test methods. Further 
case studies target the application level in the context of safety 
assessment, demonstrating that SEURAT is indeed feasible. 
This is discussed in the context of a conceptual framework for 
a modern safety assessment approach, emerging from the work 
within SEURAT-1 and related international activities. Finally, 
the SEURAT-1 approach is evaluated against the recommenda-
tions from the roadmap for the development of non-animal test 
methods for the replacement of in vivo repeated dose toxicity 
testing (Basketter et al., 2012).
2  The SEURAT research strategy
2.1  A mode-of-action based framework
Central to new approaches to toxicity testing is a mechanistic 
redefinition of adverse effects based on in vitro toxicity testing. 
This redefinition will require a series of prototypes to show the 
process in practice (Boekelheide and Andersen, 2010). Such a 
redefinition of adversity requires a mechanistic understanding 
of toxicity at the molecular scale as it will rely on perturbation 
of pathways rather than description of effects on apical end-
points. In a phase of transition it is, however, reasonable to har-
monize the current definition of adversity at the organ level (as 
apical endpoints) with the new pathway-based paradigm. This 
describes the positioning of SEURAT-1 in the field of repeated 
dose systemic toxicity, with a focus on organ toxicity (mainly 
on the liver) that needs to be linked with the development of 
understanding of molecular-scale processes. The guiding prin-
ciple of the SEURAT research strategy is, therefore, to adopt a 
toxicological mode-of-action framework to describe how any 
substance may adversely affect human health. This knowledge 
will then be used to develop complementary theoretical, experi-
mental (in vitro) and computational models that predict quanti-
tative points of departure needed for safety assessment. Finally, 
SEURAT-1 is targeting a proof-of-concept level, showing how 
the scientific tools and knowledge developed can be combined 
to deliver decision support systems for safety assessment. These 
fundamental considerations for SEURAT-1 and beyond are 
summarized in Fig. 2.
The mode-of-action framework is based on the premise that 
any adverse human health effect caused by exposure to an exog-
enous substance can be described by a series of causally linked 
biochemical or biological key “events” that result in a patho-
Fig. 2: The SEURAT vision and strategy triggers the 
formulation of proof-of-concept case studies addressed 
within SEURAT-1
Fig. 3: Schematic illustration of a sequence of events contributing to an Adverse Outcome Pathway, including the Mode-of-
Action and Toxicity Pathways as sub-sequences
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logical endpoint or disease outcome (Boobis et al., 2008). An 
“adverse outcome pathway” is a similar concept proposed by 
the computational toxicology community (Ankley et al., 2010), 
where the linking of a chemical with a pathway that leads to an 
adverse human health or ecological outcome is determined by 
its ability to trigger the associated “molecular initiating event.” 
Another related framework is that of “toxicity pathways” intro-
duced by the NRC (Krewski et al., 2010), where the description 
of toxicological processes tends to focus on early events at the 
molecular and cellular level. Thus, one can consider toxicologi-
cal pathways as critical upstream elements of a more expansive 
mode-of-action or adverse outcome pathway description of how 
a chemical can compromise human health (Kleensang et al., 
2014; Fig. 3). In addition, looking at stress response pathways 
may provide insights into toxicological mechanisms. Conceptu-
ally, stress response pathways are not perturbations but respons-
es to perturbations and, as such, their activation by chemicals 
indicates what kind of biological process was disturbed (Jen-
nings, 2013) without looking at downstream apical endpoints 
that may be very diverse. Hence, stress response pathways (such 
as the activation of the Nrf2 pathway in the context of the induc-
tion of oxidative stress) are valuable targets for toxicity testing 
(Krewski et al., 2011).
Mode-of-action theory is still emerging, but already a number 
of important principles have shaped the SEURAT research strat-
egy. The first is that every toxicant can be associated with one 
or more mode-of-action categories. To facilitate this, however, 
a suitable ontology that describes all the possible modes of 
toxicological action needs to be developed by harvesting and 
organizing the wealth of knowledge and information available 
from the literature on well-studied chemicals and pharmaceuti-
cals (Hardy et al., 2012). Systematically checking “reference” 
chemicals against mode-of-action categories will help to chal-
lenge and refine the mode-of-action ontology as it emerges, and 
will identify a wide range of key biological events and pathways 
that should be represented in relevant experimental (in vitro) 
and computational models. At the level of interactions between 
chemicals with biological targets, toxicity can be broken down 
into two categories of selectivity and three categories of reversi-
bility (Fig. 4): (i) chemicals designed to interact selectively with 
specific biological targets (such as drugs and pesticides) through 
high affinity receptor interactions that are in general reversible; 
other “non-selective” chemicals that can interact with many bio-
logical targets, either (ii) irreversibly (such as alkylating agents) 
or (iii) reversibly (e.g., low affinity receptor interactions that can 
perturb multiple cellular targets within a narrow concentration 
range). Correctly binning the chemicals into each of the three 
categories will serve as the first step for evaluating the potential 
mode-of-action of a chemical (Thomas et al., 2013).
This framework assumes that many modes-of-action share 
common key molecular or biological events. Thus, it is the par-
ticular chain of causally linked events that makes a mode-of-
action unique. In the case where a substance is promiscuous and 
could trigger multiple modes-of-action, the concentration and 
persistence of the substance at the initiation sites will dictate the 
modes-of-action that will tend to dominate. Thus, in many cases 
chronic low-dose effects may be quite different from high-dose 
acute effects. For example, carbon tetrachloride induces fully 
reversible massive necrotic cell death in perivenous hepatocytes 
upon a single high dose, but irreversible damage (fibrosis) up-
on repeated doses (Hoehme et al., 2010). A second example is 
phenobarbital, a barbiturate that causes a locus-specific change 
in the DNA-methylation pattern of mice after several weeks of 
exposure, which is not seen after short-term exposure (Thom-
son et al., 2013). This change in the DNA methylome causes a 
corresponding change in the transcriptome, triggering the tumor 
promoting effect of the barbiturate seen after chronic treatment 
but not seen after acute exposure, which only causes adaptive 
and fully reversible liver growth and an enzyme induction re-
sponse aimed at facilitating elimination of the drug from the 
body (Thomson et al., 2013). However, according to Haber’s 
Rule, such discrepancies do not occur for the so-called “c x t-
compounds,” for which a toxicological effect is the result of the 
total dose over a period of time, such that even very small dos-
es, given for prolonged periods of time, will produce the same 
toxic effect as a high dose given for only a short period of time. 
Special consideration needs to be given, therefore, to character-
izing dose-response relationships, to describing how and when 
mode-of-action transitioning may occur for a single substance, 
depending on factors such as exposure dynamics, site of action, 
genetic and epigenetic predisposition, and inherent phenotypic 
vulnerabilities. Consequently, establishing an animal-free test-
ing paradigm requires careful consideration of both the in vitro 
biokinetics of the substance of interest and its toxicodynamics 
as a prerequisite for quantitative in vitro to in vivo extrapolation 
(Blaauboer et al., 2012; Groothuis et al., 2013). 
Even though, a priori, it is not clear whether the biological key 
events relevant for repeated dose systemic toxicity differ from 
those relevant for acute toxicity, it is reasonable to assume that 
there is at least some mechanistic overlap between both expo-
sure scenarios. As most current mechanistic information stems 
from the acute exposure scenario, a pragmatic first step when 
putting the mode-of-action theory into practice in the context of 
repeated dose systemic toxicity is the clarification of differences 
regarding key events between both exposure scenarios. These 
differences may be fully controlled by the biokinetics (accumula-
Fig. 4: Chemical reactivity triggers initial interactions with 
biological targets and downstream modes-of-action 
Note that the toxicological endpoint is not indicative for the type of 
the initial interaction.
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indicating changes in the activity of selected signaling or meta-
bolic pathways. Such tailor-made reporter cell lines allow the 
capture of specific key events within particular modes-of-action 
(Wink et al., 2014). 
Complementing the cell and tissue models, computational 
chemistry, quantitative structure-activity relationships (QSARs) 
and chemoinformatics tools, such as software made available 
through the QSAR toolbox (OECD, 2014a), provide the means 
to understand and predict key biochemical events such as pro-
tein binding and metabolic transformation. The attention within 
SEURAT-1 focuses on finding associations between the struc-
tural features of a chemical and its ability to trigger the key bio-
molecular events that initiate toxicological responses that may 
lead to adverse health outcomes (Ellison et al., 2011). Forming 
chemical categories based on combined structure-activity de-
scriptors will ultimately facilitate more rapid and robust hazard 
profiling of chemicals and read-across between chemicals that 
have similar modes-of-action. 
Another important aspect of the SEURAT strategy is the em-
phasis placed on understanding and predicting the in vivo bioki-
netics of exogenous chemicals. Quantifying the dose in different 
target tissue compartments as a function of time and exposure 
conditions is a fundamental requirement of any predictive toxi-
cology paradigm (NRC, 2007a). In particular, the establishment 
of an in vitro testing paradigm requires methods to extrapolate 
in vitro concentrations to the in vivo situation, taking into con-
sideration the in vitro biokinetics (Groothuis et al., 2013) and 
the high sensitivity of omics data to the dosing protocol as well 
as to the time point of the respective analyses (Blaauboer et al., 
2012). First models calculating in vivo concentrations and ex-
posure based on in vitro data were already developed for this 
purpose (Wetmore et al., 2012; Yoon et al., 2012). These models 
are adapted to the research work within SEURAT-1 (Péry et al., 
2013).
In summary, SEURAT-1 has a work program that aims to 
demonstrate a proof-of-concept for the scientific and technolog-
ical underpinning of the SEURAT strategy. The overall empha-
tion in the cells versus transformation rates; the latter may cause 
metabolic activation) leading to: (i) repeated hits (of the paren-
tal compound or metabolites) on the same molecular target; (ii) 
overload of defense/repair mechanisms through accumulation of 
a chemical (parental compound or metabolites) at certain initia-
tion sites; (iii) progressive change in the epigenome; (iv) effects 
on the immune system, such as proliferation of memory cells 
and progressive activation and transformation of, e.g., hepatic 
stellate cells; and finally (v) induction of a sequence of adverse 
reactions involving different cell types (and organs). 
 Another principle to be considered concerning mode-of-ac-
tion theory is that many key events and pathways are common 
to many cell types throughout the human body (for example, the 
Nrf2-pathway; Krewski et al., 2011). Thus, although the same 
substance can cause different pathological outcomes in different 
tissues, the upstream event, such as inhibition of mitochondrial 
function or generation of reactive oxygen species, may be com-
mon to the modes-of-action triggered at each site. Conversely, 
certain modes-of-action involve key events or pathways that 
are associated with specific biological functions expressed by 
particular cell types. For example, the presence of metaboliz-
ing enzymes in liver cells may bioactivate exogenous chemicals 
to produce toxic metabolites, or the presence of cell membrane 
transporters required for the uptake of certain toxicants. Simi-
larly, the presence of receptors for neurotransmitters in neuronal 
cells can be targeted by toxicants. This is another example of 
cell-specific properties that can be implicated in a toxicological 
mode-of-action.
2.2  Implications for in vitro and in silico toxicity 
testing: The SEURAT-1 approach
Establishing a comprehensive description of the mode-of-action 
domain is a challenging element of the strategy and requires the 
use of advanced discovery and modelling tools to identify the 
key biological events and biomarkers that comprise a particu-
lar mode-of-action. Elucidating the relationship between these 
events can benefit greatly from high content functional analy-
sis tools such as transcriptomics and proteomics (Wilmes et al., 
2013). These data are used to guide the definition of systems 
biology models which capture the process dynamics and allow 
quantitative prediction of biological pathway perturbation. As 
the mode-of-action framework is refined, and more key biologi-
cal events are identified, new biomarkers of effect can be incor-
porated into assay systems. 
In order to overcome any shortcomings regarding translation 
of mode-of-action theory into test system development through 
inter-species variability, SEURAT-1 researchers are using 
human-based cell lines as biological models (established cell 
lines, primary cells and stem cell-derived cell lines). Stem cell-
derived cell lines were thoroughly characterized to evaluate for 
which exact purpose they are fit (Pistollato et al., 2012). Biore-
actor technology is being employed to engineer 3D tissue con-
structs in vitro in an attempt to capture the intricate interactions 
between different cell types present in an organ that must work 
in unison to maintain homeostasis and function. Furthermore, 
genetically engineered stem cell-derived models are being gen-
erated that are equipped with reporters which are suitable for 
Fig. 5: Key elements of SEURAT-1 and perspectives  
for a possible second phase of SEURAT
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failed drugs since these molecules typically have specific mech-
anisms or modes-of-action that are extensively described in the 
literature. It is precisely these mode-of-action-related properties 
that make them reliable candidates for nomination as reference 
compounds, rather than their actual origin or commercial use. 
3.2  The proof-of-concept case studies
3.2.1  Why case studies?
The SEURAT-1 Research Initiative aims at delivering many 
important computational and experimental tools and related 
knowledge that will be critical components in predictive toxi-
cology approaches. To demonstrate the potential of these tools 
and how they can be assembled in an integrated manner, the 
cluster undertakes a proof-of-concept exercise, separated into 
three distinct areas: theoretical (mode-of-action descriptions), 
methodological (development of integrated testing strategies 
according to modes-of-action) and application (aiming at im-
proved, animal-free safety assessment approaches). 
In this way, SEURAT-1 is following a case study approach. 
Adopting a mode-of-action toxicological framework as outlined 
above means that one needs to learn by doing, with the start-
ing point being identifying some “prototype” modes-of-action 
that could be elaborated. Covering all potential modes-of-action 
based on existing knowledge is simply not feasible. Hence, be-
ing selective is important at the beginning of this endeavor – 
“selective” in terms of chemicals (see above, chemical selec-
tion), modes-of-action, and definition and design of case studies 
to prove the underlying concepts. The following quote, taken 
from an article that discussed some fundamental considerations 
about the way forward in predictive toxicology, summarizes the 
motivation behind the SEURAT-1 case study design: 
“... in the near-term, however, what is most needed 
is a demonstration of the feasibility of these new ap-
proaches and their ability to be both reliable and pre-
dictive. These near-term goals ... can most effectively 
be met with demonstration projects using a case study 
approach” (Andersen et al., 2011).
3.2.2  Mode-of-action descriptions
Proof-of-concept at the theoretical level aims to show how 
toxicological knowledge concerning modes-of-action can be 
mined, or perhaps generated, and then reconciled, consolidated 
and explicitly described in a format that can be managed and 
communicated in an effective and harmonized manner. For 
this purpose, the International Programme on Chemical Safety 
(IPCS) of the World Health Organisation (WHO) has published 
guidance (Boobis et al., 2008) on what type of information 
should be provided to describe a mode-of-action (MoA) and, 
just as importantly, how the relevant evidence should be pre-
sented to demonstrate the validity of the proposed description. 
More recently, the OECD has followed this direction by pro-
posing an analytical tool termed “adverse outcome pathway” 
(AOP, see above), and published a template for capturing the 
relevant information (OECD, 2013). This template clearly in-
dicates which information should be provided, both to describe 
the toxicological process itself and the evidence that supports 
sis is on the identification and elucidation of modes-of-action 
related to repeated dose systemic toxicity in humans, and the 
development of experimental and computational models that ef-
fectively capture the related pathways and key biological events 
(Fig. 5). A set of reference chemicals has been compiled from 
chemicals that have been thoroughly investigated regarding 
their chronic toxicological action in animals and, if possible, in 
humans. This information was used to propose an initial mode-
of-action framework to which the various research activities can 
refer (see below). 
Aiming at a more quantitative description of a mode-of-action 
requires mathematical models of sufficient complexity. Systems 
biology theory and tools provide a strong basis for these models 
(Kohonen et al., 2014) that needs to be integrated into a multi-
scale modelling framework connecting subcellular events with 
effects at the organ scale (Niklas et al., 2013). As the mode-of-
action framework becomes more established and the range of 
validated models grows, an increasing number of chemicals can 
be profiled to establish in which mode-of-action categories they 
belong. This will then facilitate read-across within categories 
and provide the basis for ultimately predicting hazard threshold 
values, akin to in vivo no-effect levels. 
3  Implementation of the research strategy
3.1  Chemical selection
The first sign of how the guiding principles of the research 
strategy outlined above have influenced the research cluster is 
reflected in the approach adopted for the selection of standard 
reference compounds to be used across the projects. The selec-
tion of standard reference compounds is a critical issue in any 
research program and a cross-cluster working group led by the 
servicing project ToxBank was established within SEURAT-1 
for defining selection criteria according to the overarching re-
search strategy and, ultimately, providing the research projects 
with a list of reference compounds. The selection was governed 
by the following basic considerations: (i) The standard refer-
ence compounds should be associated with well-known modes-
of-action; (ii) the standard reference compounds should be rel-
evant for repeated dose toxicity; (iii) promiscuity, i.e., lack of 
structural specificity in ligand binding, should be considered; 
and (iv) extrapolation from well-studied reference compounds 
to a broader chemical space, taking into account different up-
take routes, should be possible. 
Consequently, the working group first identified and described 
a range of known modes-of-action more commonly cited in 
repeated dose toxicity studies, and then picked molecules for 
which there is ample mechanistic evidence of association with 
toxicological effects or pathways underpinning those modes-
of-action. The resulting list of standard reference compounds is 
now publicly available as an online resource (ToxBank, 2014) 
along with extensive descriptions with respect to the above-
mentioned criteria, including further considerations regarding 
their applicability in cell-based in vitro assays (e.g., long shelf-
life, soluble in buffer, commercially available, etc.). Not surpris-
ingly, many of the reference chemicals are pharmaceuticals or 
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such AOP descriptions. Note that SEURAT-1 is entirely focusing 
on the replacement of animal tests by the application of human 
cells and, thus, will not conduct in vivo experiments. Therefore, 
the development process relies heavily on a systematic review 
of the literature and publicly available toxicity study databases 
to extract the mechanistic knowledge applicable to the MoA in 
the postulation of the associated key events, including the mo-
lecular initiating event (Fig. 6A). Examples of AOP descrip-
tions based on this concept were published recently (Vinken, 
2013; Vinken et al., 2013).
The ongoing selection of modes-of-action (MoA) within 
SEURAT-1 is performed in the context of the development of 
Fig. 6: Prototype mode-of-action descriptions developed within SEURAT-1
A: Generic mode-of-action description causally linking a molecular initiating event (MIe) with an adverse outcome (AO) at the organ or 
organism level by identifying intermediate key events and connecting them with biological plausibility with the MIe and AO, respectively 
(OECD, 2013). The key events are the basis for hypothesis development and testing and should be experimentally quantifiable. 
B: Collection of key events connecting chemical-induced liver fibrosis (AO) with protein alkylation (MIE) to be used as anchors for toxicity 
testing (TGF-β1: transforming growth factor beta 1). A mechanistic description assembling the key events in a biologically plausible way 
can be found elsewhere (landesmann et al., 2012; Vinken, 2013). 
C: Collection of key events (ChReBP: carbohydrate response binding protein; SReBP-1c: sterol response element binding protein;  
FAS: fatty acid synthase; SCD1: stearoyl-coenzyme A desaturase 1; CD36: fatty acid translocase) connecting chemical-induced liver 
steatosis (AO) with the activation of the liver x receptor (MIe; landesmann et al., 2012; Vinken, 2013). 
D: Collection of key events (PxR: pregnane x receptor; CAR: constitutive androstane receptor; FxR: farnesoid x receptor;  
SHP: small heterodimeric partner; OSTα/β: organic solute transporter α/β; MRP2, 3: multidrug resistance associated proteins 2  
and 3; CYP2B10, 3A4, 7A1: cytochrome P450 2B10, 3A4, 7A1; UGt2B4: uridine 5’-diphosphate-glucuronosyltransferase 2B4; SUlt2A1: 
dehydroepiandrosterone sulfotransferase; NtPC: sodium/taurochlorate cotransporter; OAtP1B1: organic anion transporter 1B1;  
MPP: mitochondrial permeability pore) connecting chemical induced cholestasis (AO) with the inhibition of the bile salt export pump 
(BSeP, MIe). Further mechanistic explanations can be found elsewhere (Vinken et al., 2013).
Gocht et al.
Altex 32(1), 201516
tion. Subsequently, bile salt accumulates in the cytosol, induc-
ing both adaptive and deteriorative cellular responses: cytosolic 
bile acid accumulation triggers transcriptional changes (acti-
vation of the pregnane X receptor (PXR), the constitutive an-
drostane receptor (CAR) and the farnesoid X receptor (FXR), 
which induces the gene silencer small heterodimeric partner 
(SHP)), leading to deregulation of a number of proteins (up-
regulation: organic solute transporter α/β (OSTα/β), multidrug 
resistance associated proteins 2 and 3 (MRP2, 3), cytochrome 
P450 2B10, 3A4 (CYP2B10, 3A4), uridine 5’-diphosphate-glu-
curonosyltransferase 2B4 (UGT2B4), dehydroepiandrosterone 
sulfotransferase (SULT2A1); down-regulation: sodium/tauro-
chlorate cotransporter (NTCP), organic anion transporter 1B1 
(OATP1B1) and cytochrome P450 7A1 (CYP7A1)), which is 
considered as an adaptive cellular response counteracting the 
primary cholestatic insults. This is distinguished from a deterio-
rative cellular response (formation of the mitochondrial perme-
ability pore (MPP), oxidative stress and inflammation) leading 
to necrosis and apoptosis. A complete overview and mechanistic 
interpretation of this MoA description along with a weight of 
evidence assessment discussing the confidence in this construct 
was published recently (Vinken et al., 2013).
3.2.3  Systems to predict toxicity
At the systems level, the intention is to demonstrate how test 
systems can be produced by integrating various in vitro and in 
silico tools emanating from the SEURAT-1 projects, in order to 
assess the toxicological properties of chemicals using modes-
of-action as an analytical basis. These systems can then be used 
to develop a robust and predictive data integration approach for 
safety evaluation, while minimizing uncertainties in the pre-
diction through mechanistic understanding. Such systems in-
clude a combination of computational chemistry models with 
a battery of in vitro assays to generate a mixed set of chemical 
structure and bioactivity descriptors that can be used to group 
chemicals into MoA-based categories. The approach for design-
ing MoA-based integrated testing strategies is currently under 
development and will be reported separately. In essence, the 
identification of key events in the process of developing a MoA 
description provides the backbone of an MoA-based integrated 
testing strategy. Test systems focus on certain key events and 
their sensitivity and specificity will be assessed by a sophisti-
cated selection of standard reference compounds demonstrating 
that the test system is indeed predictive for the mechanism ad-
dressed (which follows a strategy of “mechanistic validation”; 
Hartung et al., 2013b). 
The overall aim of this exercise is to predict certain aspects of 
toxicity of a chemical that are primarily related to the above-de-
scribed modes-of-action for liver toxicity. Other organs are also 
represented in the selection of case studies, which will allow 
differentiation between organ-specific and more general path-
ways. Note that the MoA description need not be complete to be 
used as a blueprint in the design of the integrated testing strat-
egy, and may be further developed iteratively when results from 
the testing strategy addressing a particular MoA become avail-
able. By these means, further experimental elucidation of the 
MoA will lead to confirmation and refinement or reformation of 
question. Considering the wealth of information already avail-
able, a MoA description can be typically brought to a relatively 
mature state of development by studying relevant review papers 
and reported studies. However, at some point the process pla-
teaus since the finer mechanistic detail specific to the MoA is 
often lacking in the description. Thus, more extensive develop-
ment of a MoA can require the undertaking of prospective ex-
perimental (in vitro) investigations that are specifically designed 
to shed light on the less understood aspects of the MoA. 
Given the high number of hepatotoxins in the list of SEURAT-1 
standard reference compounds as a result of the chemical selec-
tion strategy (ToxBank, 2014), it was reasonable to start the ex-
ercise with MoA descriptions that are of relevance to the liver 
and to try to define related pathways based on the identification 
of interactions of a chemical with known targets. As a result, 
the following three prototype MoA descriptions were assembled 
(Fig. 6B-D):
From protein alkylation to liver fibrosis, Fig. 6B
Liver fibrosis is a potentially reversible wound healing response 
to a variety of chronic as well as acute injuries including those 
due to toxic insults. It results from a complex interplay between 
various cell types (hepatocytes, Kupffer cells and stellate cells) 
and signaling pathways with transforming growth factor beta 1 
(TGF-β1) expression and activation of hepatic stellate cells as 
key events (Brenner, 2009). This MoA description was assem-
bled by Landesmann et al. (2012) and is summarized by Vinken 
(2013) with further information about the interplay between the 
key events. 
From liver X receptor activation to liver steatosis, Fig. 6C
Liver steatosis (fatty liver) is characterized by the micro- or mac-
rovesicular accumulation of lipid droplets in the liver (Amacher, 
2011). The development of steatosis can be attributed to many 
different causes, including interactions of chemicals with nu-
clear receptors that are involved in hepatic lipid metabolism. 
Among others, the activation of the liver X receptor (LXR), 
which is involved in fatty acid homeostasis, cholesterol metabo-
lism and in the control of inflammation (Zelcer and Tontonoz, 
2006), was identified as one important molecular initiating event 
triggering liver steatosis (Ducheix et al., 2013). LXR activation 
induces transcriptional changes (activation of the expression of 
the carbohydrate response binding protein (ChREBP), the sterol 
response element binding protein 1c (SREBP-1c), fatty acid 
synthase (FAS) and stearoyl-coenzyme A desaturase 1 (SCD1)), 
and up-regulation of the fatty acid translocase (CD36) produc-
tion. More details and a flow chart summarizing this MoA can 
be found elsewhere (Landesmann et al., 2012; Vinken, 2013).
From bile salt export pump inhibition to liver  
cholestasis (Fig. 6D)
Liver cholestasis results from obstructed bile flow from the liv-
er to the duodenum. Besides mechanical reasons (gallstones), 
the inhibition of transporters such as the bile salt export pump 
(BSEP) plays a key role in this liver injury. Various chemi-
cals can directly inhibit the BSEP (Padda et al., 2011), which 
serves as the molecular initiating event in this MoA descrip-
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tion 3.2.3 above), are being undertaken as key contributions 
to the proof-of-concept of the SEURAT-1 approach at the ap-
plication level: an ab initio approach, in which the point-of-
departure (POD) for safety assessment will be mechanistically 
derived from in silico and in vitro tools, i.e., with the informa-
tion combined in a rational manner; and a read-across approach, 
in which the toxicological properties (in effect the POD) will 
be predicted by “reading across” from analogue substances of 
known toxicological properties also using in silico and in vitro 
tools to support the prediction.
Ab initio case study
This case study will translate findings and data from the integra-
tion of relevant case studies from the systems level (see Section 
3.2.3) for quantitative mechanistic safety assessment. The ambi-
tion is to demonstrate the feasibility of the SEURAT-1 approach 
to support the prediction of human health. Ultimately, the pre-
diction goal is to determine a safe dose of an ingredient within a 
consumer use scenario, but this quantitative mechanistic safety 
assessment approach is the most ambitious scenario and rep-
resents the long-term perspective of putting tools of predictive 
toxicology into practice rather than demonstrating complete ap-
plication cases within SEURAT-1. This is mainly due to the fact 
that it would require either complete knowledge about toxico-
logical modes-of-action (including methods to evaluate the most 
sensitive pathways for non-selective chemicals that could affect 
multiple pathways), or a test system that covers all these poten-
tial pathways. Both are far beyond the scope of SEURAT-1, and 
the strategy of using prototype modes-of-action as a basis for 
case study design intends to produce “islands of knowledge”, 
from which safe doses of chemicals can be derived only with re-
spect to these particular modes-of-action. These shortfalls will, 
in the near-term, limit the application of this approach; i.e., it 
will not be adequate to assess a specific substance for regulatory 
purposes. Nevertheless, it explores how far the tools and meth-
odology that will be available by the end of SEURAT-1 can be 
extended. Of course, the exercise is also designed to highlight 
major knowledge gaps and thereby provide a clear indication 
on where future research and development efforts in the field of 
safety assessment need to focus, bearing in mind that compiling 
a comprehensive list of all toxicity pathways as sub-sequences 
of toxicological modes-of-action is the goal of projects focusing 
on mapping the human toxome (Hartung and McBride, 2011). 
The obvious way of starting this endeavor is to select a few 
of the SEURAT-1 standard reference compounds (see Section 
3.1 and ToxBank, 2014) with known modes-of-action to evalu-
ate the predictive toxicity systems (see Section 3.2.3) supported 
with additional methods developed within SEURAT-1. Further 
data-rich test chemicals can then be selected from existing da-
tabases or published surveys which classify chemicals accord-
ing to target organs and suspected modes-of-action following 
repeated exposure to chemicals (e.g., Vinken et al., 2012). 
Read-across case study
The read-across approach is probably best known for hazard 
and safety assessment of industrial chemicals under REACH, 
but is often employed in other sectors too (Patlewicz et al., 
the theoretical model. Conversely, to select methods for toxicity 
prediction, it might be sufficient to select one dominating key 
event rather than looking into a detailed MoA description.
Two main questions should be addressed when planning the 
development of respective in vitro test systems: (i) What is the 
appropriate biological model (based on the requirements, i.e., 
the prediction goal of the system, that needs to be defined be-
forehand); and (ii) what is the most relevant in vitro treatment 
protocol to relate to the human in vivo exposure (concentrations, 
dosing frequency, time interval after exposure when the end-
point should be measured)? There is no general approach, but 
recommendations to address these issues appropriately based on 
a decision tree that considers the properties of the chemical of 
interest, the assay setup and the MoA measured in the assay 
were published recently (Groothuis et al., 2013). 
Although experimental investigation to elucidate mechanisms 
and modes-of-action is an important activity within SEURAT-1, 
there is widespread acknowledgement that mining publicly 
available databases that report both in vitro and in vivo toxic-
ity studies (e.g., the “Open TG-GATEs” database established 
by the Toxicogenomics Project in Japan, or the DrugMatrix da-
tabase of the U.S. National Toxicology Program) can provide 
an invaluable source of MoA information. In particular, there is 
an enormous amount of toxicogenomics data that, with the ap-
propriate analysis, could uncover hidden mechanisms and key 
events and provide supporting evidence for a MoA during its de-
velopment and evaluation (Kongsbak et al., 2014). SEURAT-1 
case studies use data mining approaches for the elucidation of 
pathways through integrated analysis of omics data as well as 
for the validation of biomarkers for toxicity, which were discov-
ered within the case studies. 
3.2.4  Application in safety assessment
At the highest level, proofs-of-concept address the desire to 
show how the data and information derived from the tools and 
methods developed within SEURAT-1 can be used in specific 
safety assessment frameworks and scenarios. This could include 
the assessment of hazardous properties to screen a large set of 
substances to select groups with particular characteristics or to 
assess a specific substance. Again, the selection of chemicals is 
key for the formulation of case studies in the context of safety 
assessment and will strongly influence the case study design, 
simply due to the lack of validated animal-free testing methods 
addressing repeated dose systemic toxicity. From this perspec-
tive, the chemicals selected for the formulation of mode-of-ac-
tion descriptions and the design of respective integrated testing 
strategies can be considered to be data-rich chemicals. Indeed, 
these chemicals were selected because of their well-known toxi-
cological properties (see Section 3.1). The general problem in 
safety assessment scenarios, however, is the prediction of the 
toxicological effects of chemicals with a very limited amount of 
available information (data-poor) and to find appropriate data-
rich candidate chemicals to be used as counterparts or indicators 
for assessing data-poor chemicals. Furthermore, the prediction 
must comprehensively evaluate all possible effects (MoA) for 
a chemical to ensure its safety. Two case studies, supported by 
the test systems to be developed within SEURAT-1 (see Sec-
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essentially equivalent to the omitted standard animal study and 
it must be adequate for classification and risk assessment. The 
basic idea of the case study is to strengthen traditional read-
across approaches with additional new in vitro data to reach 
the necessary REACH standard when the structural similarities 
would be insufficient without this supporting evidence. An im-
portant aspect of the case study is to decide how to determine 
the added value of the SEURAT-1 information. This could be by 
expert judgment of the case before and after the extra evidence 
is added to give a qualitative assessment of the robustness of 
the toxicity prediction. In some cases classical animal toxicity 
data on the target substance may exist against which the “read-
across” predictions may be tested (with and without SEURAT-1 
evidence). Hence, chemicals for the read-across case study were 
selected “top-down”, independent of the criteria for the selec-
tion of SEURAT-1 standard reference compounds (see Section 
3.1), but considering: (i) indications for an association with re-
peated dose toxicity, and (ii) relevance to industry. The selected 
chemicals fall into four read-across scenarios: (i) direct-acting 
toxicants (no metabolism); (ii) chemicals involving metabolism; 
(iii) chemicals with general low or no toxicity: and (iv) chemi-
cals with high toxicity and specific modes-of-action. Further 
practical guidelines about how to perform read-across studies 
can be found elsewhere (ECHA, 2013a,b).
This case study is a realistic target within SEURAT-1 that will 
be of practical regulatory use within the short term and, hence, 
reduce animal testing. It will also be a practical outcome from 
SEURAT-1 that demonstrates a particular application of the ap-
proach of the “conceptual framework” (Section 4), thus giving 
reassurance that the broader application of the approach to ab 
initio prediction of toxicological properties will be feasible.
4  Conceptual framework for a rational integrated 
assessment strategy
Following earlier work in the field of regulatory toxicology 
(e.g., Gubbels-van Hal et al., 2005), the intention of the safety 
assessment case studies (see Section 3.2.4) is to bridge the gap 
between safety assessment decision-making and innovative pre-
dictive systems being developed within SEURAT-1. The aim is 
to harness the mechanistic outputs with an emphasis on how 
emerging science can best impact and reshape current safety as-
sessment practice, focusing on the application level to identify 
pragmatic ways to use information derived from predictive tools 
to support safety assessment processes and decisions. While 
pulling together the various elements of SEURAT-1 in order to 
formulate the case studies and provide context for where the 
various strands of work being undertaken can be aligned and 
incorporated, a flexible “conceptual framework” has emerged 
that can be used as a basis for the rational combination of infor-
mation derived from predictive tools to support a safety assess-
ment process or decision that achieves a stated protection goal 
in the context of repeated dose systemic toxicity (Fig. 7). Simi-
lar to previous schemes that were developed to implement in 
vitro and in silico approaches into regulatory safety assessment 
(e.g., Blaauboer et al., 1999), this framework is intended to set 
2013). Traditional read-across relies on the concept that chemi-
cal similarity leads to similar chemical and physical properties, 
and thus to similar toxicity; i.e., the basis is primarily on chemi-
cal similarity, but with biological similarity as a supplementary 
consideration. Such predictions can be confounded due to the 
underlying complex mechanisms of toxicity. The credibility of 
the scientific argument to support read-across can be supported 
by other information including test data. Hence, information 
from in vitro molecular screening, omics assays and compu-
tational models can be used to improve the robustness of the 
read-across justification (OECD, 2014b). The SEURAT-1 case 
study on read-across aims to demonstrate that the robustness 
of read-across of repeated-dose oral toxicity from a source 
substance of known toxicology to target substance(s) can be 
improved using SEURAT-type evidence. In effect, in this new 
approach SEURAT-1 data is used as supporting evidence to 
improve the confidence in read-across based on similarity in 
chemical structure and is equivalent to adding an examination 
of biological similarity (as modelled by multiple short-term as-
says). Indeed, integrated chemical-biological read-across argu-
ments appear to be more robust as compared to the traditional 
approaches focusing on chemical similarity alone (Low et al., 
2013). Following this principle, an advanced two-step proce-
dure that combines chemical and biological considerations as 
well as toxicological data as search criteria for the identifica-
tion of the analogues (first step) with an approach to categorize 
the identified analogues (second step) was implemented (Wu 
et al., 2010). This framework was successfully applied in read-
across case studies (Blackburn et al., 2011). The process did not 
always result in surrogate values for risk assessment and also 
highlighted cases where read-across could not be performed; 
thus, data gaps to be addressed in future work were identified. 
In addition, a decision tree for the application area of develop-
mental and reproductive toxicity emerged from these exercises, 
which was then further developed and can now be used as a 
screening tool to identify chemicals with a potential for devel-
opmental and reproductive toxicity (Wu et al., 2013). Further-
more, as the chemical groupings generated in this process rely 
on chemical and biological principles, they may be useful start-
ing points for the formulation of hypotheses regarding respec-
tive modes-of-action and the development of corresponding in 
vitro test methods (Wu et al., 2013). This procedure can act 
as a model and the framework adapted to other fields such as 
repeated dose systemic toxicity and, through the delivery of ad-
ditional mode-of-action descriptions, may potentially advance 
the overall SEURAT1 approach.
It should be noted that the read-across approach is fundamen-
tally different from the ab initio case study. The primary goal 
here is to show a real case of how non-animal methods can now 
be used to support decision-making in the regulatory context 
of safety assessment. Specifically, the aim of the read-across 
case study is to meet the standard for filling a REACH registra-
tion information requirement. Conceptually, this means that the 
complete set of results and findings of a 28-/90-day repeated-
dose oral rat toxicity study on the “source” substance should 
be able to be “read across” to the target substance (which has 
not been studied in animals). The idea is that this prediction is 
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The aim within SEURAT-1 is to set the framework and show 
how mechanistic safety assessment could proceed through 
specific case studies and make a start in filling the details of 
the strategy and identify knowledge gaps and areas for fur-
ther development. The need to develop guidance on the use of 
physiologically-based models in chemical risk assessment that 
includes toxicokinetic and toxicodynamic models incorporating 
in vivo, in vitro and in silico data was highlighted recently in a 
report published by the European Food Safety Authority (EFSA, 
2014). The SEURAT-1 standard reference compounds identified 
provide an initial basis for work to proceed as they comprise 
known human relevant toxicants that we can benchmark the 
framework against. Nevertheless, we need to be able to general-
ize the approach to more generic chemistries, and the flexible 
conceptual framework may provide the basis for doing so.
The SEURAT-1 toxicological mode-of-action approach in-
corporates the overall principles of this framework, taking into 
account the particular chemical and its properties, as well as 
the (regulatory) purpose to deliver a fit-for-purpose prediction. 
SEURAT-1 focuses, however, on chemicals interacting selec-
tively with a limited number of biological targets, for which the 
assessor needs to identify the respective modes-of-action (i.e., 
following the sequence on the right-hand side in Fig. 7). The 
next step is to determine the ADME-properties for the chemi-
cal of interest to predict the internal dose at the target organ. A 
battery of in silico and in vitro tools combined in an integrated 
testing strategy will then validate the suspected mode-of-action 
and, based on methods of reversed dosimetry (Yoon et al., 
out a structure to guide assessors in devising a fit-for-purpose 
bespoke integrated assessment and testing approach (IATA) for 
the particular circumstances and case. The overall outcome is 
anticipated to be robust as it is not based on single pieces of 
evidence, but rather on a weight of evidence combined in a bio-
logically rational manner.
Before beginning the assessment, the degree of confidence 
needed for the prediction is decided. There may be an exposure 
context that enables the acceptance of a moderate or low degree 
of confidence in the prediction, possibly due to well-controlled 
and low human exposure resulting from the particular use of 
the substance. Then the idea is to begin with examining exist-
ing knowledge from different lines of evidence. In particular, it 
is important to consider if the compound is a “general chemi-
cal” expected to be unselective in interacting with biological 
targets or a drug/pesticide designed to be selectively biologi-
cally active. Other evidence could include toxicological studies 
on the substance or “read-across” from chemical or biological 
analogues, QSARs and structural alerts and expert judgment. 
Following this step there are two parallel lines of consideration: 
(i) “general” adverse effects not associated with a particular 
organ and (ii) organ-based adverse effects. Toxicokinetics/toxi-
codynamics must be considered in both lines of investigation. 
Effects on organs can be assessed by one or more AOPs with 
the molecular initiating event (MIE) and intermediate events 
(IEs) incorporating existing knowledge and with new data as a 
combination of in vitro assays (omics data, HPT data, etc.) and 
in silico predictions in a battery of tools. 
Fig. 7: The SEURAT-1 conceptual framework as a structure for safety assessors in devising a fit-for-purpose bespoke 
integrated assessment strategy for a particular case
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to adverse drug effects will be developed. Particular attention 
will focus on adverse outcome pathways related to mitochon-
drial deregulations and immunological dysfunctions. The aim of 
MIP-DILI is to develop improved tools for liver toxicity testing 
in the early stages of the drug development process. This will 
require a deepened understanding of the science behind drug-
induced liver injury and the application of this knowledge to 
overcome the many drawbacks of the tests currently used. The 
relationships of these two initiatives with SEURAT-1 are obvi-
ous: HeCaToS and MIP-DILI can build on the case study ap-
proach of SEURAT-1 and develop it further, taking the existing 
adverse outcome pathway descriptions and the respective test 
systems into account to assess their suitability for the purposes 
of: (i) assessing specific diseases (HeCaToS) and (ii) improved 
toxicity testing in drug development (MIP-DILI). 
SEURAT-1 is not only serving other projects, but also benefits 
from others: Of utmost relevance are the Tox21 and ToxCast 
research programs in the United States (US). In 2005, the US 
government launched Tox21 (http://www.epa.gov/ncct/Tox21/), 
an initiative to use in vitro high-throughput screening (HTS) to 
identify what proteins, pathways, and cellular processes chemi-
cals interact with and at what concentration they interact. Cur-
rently, the Tox21 effort has screened ~10,000 chemicals across 
nearly 50 in vitro HTS assays. Tox21 is a consortium that pools 
the resources and expertise of US Environmental Protection 
Agency, National Institutes of Environmental Health Sciences/
National Toxicology Program, National Institute of Health/
National Center for Advancing Translational Sciences, and the 
Food and Drug Administration. In parallel with Tox21, the US 
Environmental Protection Agency launched the ToxCast pro-
gram (http://www.epa.gov/ncct/toxcast/). ToxCast also utilizes 
in vitro HTS of chemicals, but has screened fewer chemicals 
(~1,800) over an expanded set of 700 biochemical and cell-
based in vitro assay endpoints (Kavlock et al., 2012). Both the 
Tox21 and ToxCast programs aim to develop high-throughput 
decision support tools for prioritizing the thousands of chemi-
cals that need toxicity testing. The experimental work is being 
accompanied by the development of models that can be used to 
more effectively predict how chemicals will affect biological re-
sponses. The different methods should be effectively combined 
as a toolbox of innovative chemical testing methods. Finally, the 
challenge of being able to provide the data generated from the 
innovative chemical testing methods to risk assessors for mak-
ing decisions about protecting human health and environment is 
addressed (see above and Thomas et al., 2013). 
The common goal of Tox21, ToxCast and SEURAT-1 is to 
implement state-of-the art technologies emerging from recent 
scientific advances into safety assessment procedures. All initia-
tives focus on a combination of in vitro methods and in silico 
tools as components of modern, innovative testing methods. 
However, the approaches of each initiative are fundamentally 
different: Tox21 and ToxCast, not restricted to any field within 
the arena of toxicology, follows a screening strategy studying a 
high number of chemicals in a very diverse set of available test 
systems. In contrast, SEURAT-1 focuses on repeated dose sys-
temic toxicity and has selected a limited number of well-studied 
chemicals for the development of mode-of-action-driven test 
2012), convert the in vitro dose response to in vivo values and 
respective environmental concentrations (exposure) as a point-
of-departure (POD) for safety assessment.
For non-selective chemicals that affect multiple biological 
pathways, toxicity profiles need to be developed based on the 
identification of structural alerts and read-across studies. Some 
general, sensitive and organ-unspecific modes-of-action (which 
are currently unknown) need to be tested to derive a POD for 
safety assessment. High-throughput screening tools distinguish-
ing between selective and non-selective chemicals using a high 
number of assays are being developed within the U.S. Tox21 
research program – the pragmatic strategy to derive the POD 
would be to use the most sensitive assay as a starting point 
(Thomas et al., 2013). The overall outcome of an assessment 
based on this framework would be robust as it is not based on 
single pieces of evidence; nevertheless the type and degree of 
uncertainty in the predictions would need to be validated as “fit-
for-purpose.”
Other schemes for evaluating chemicals using the new tools 
for toxicity testing are also under development. A data-driven 
framework based on data from a broad range of high-throughput 
in vitro assays from the Tox21 program (see Section 5 below), 
which invokes successive tiers of testing with margins-of-ex-
posure as the primary metric, was proposed recently (Thomas 
et al., 2013). This framework provides a risk-based approach to 
the evaluation of chemical safety, drawing broadly from previ-
ous experience and incorporating technological advances to in-
crease efficiency. Even though emerging from a high-throughput 
screening approach, it is fully complementary with the above-
described conceptual framework of the SEURAT-1 approach.
The discussion about these concepts and frameworks high-
lights the fact that SEURAT-1 is operating in a very dynamic 
field of research, and a number of related research projects in 
different parts of the world are active in parallel, advancing the 
field rapidly. This is briefly outlined in the following section. 
5  SEURAT-1 in the international context
5.1  Related international research activities
Related, ongoing research activities in Europe are mainly those 
under the umbrella of the European Commission’s RTD Frame-
work Programmes and the Innovative Medicines Initiative Joint 
Undertaking (IMI JU), a pan-European public-private partner-
ship between the European Commission and the European Fed-
eration of Pharmaceutical Industries and Associations (EFPIA). 
Based on common interests, concrete interactions are planned 
with HeCaToS (Hepatic and Cardiac Toxicity Systems Mod-
elling, European Commission’s 7th Framework Programme; 
http://www.hecatos.eu/) and MIP-DILI (Mechanism-based in-
tegrated systems for predicting drug-induced liver injury, IMI; 
http://www.mip-dili.eu/). The overall goal of HeCaToS is to 
develop an integrated framework for modeling toxic perturba-
tions in the liver and heart across multiple scales. Advances in 
computational chemistry and systems toxicology will be com-
bined for this purpose and case studies based on biopsies from 
patients suffering from liver injuries or cardiomyopathies due 
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spired by considerations from international experts in this re-
gard who recommended an initial focus on adverse effects in 
the liver (Kimber at al., 2011). It is not expected that SEURAT-1 
will deliver ultimate solutions, but the consortium has taken up 
important components from the roadmap for the development of 
non-animal test methods for the replacement of in vivo repeated 
dose toxicity testing (Tab. 1; Basketter et al., 2012) and, hence, 
should be well prepared to proceed on the next level.
6  Concluding remarks: Beyond SEURAT-1
The successful completion of SEURAT-1 will lay the founda-
tion for follow-on efforts that will broaden the toxicological, 
chemical and regulatory domains addressed. The intention of 
SEURAT-1 is to provide a blueprint for future implementation 
of knowledge-based test systems into new safety assessment 
approaches. New approach methods and biological thinking 
can be used in two ways: (i) for hazard (and risk) assessment 
adapted into the current regulatory “paradigm”, and/or (ii) to 
incorporate approaches for regulatory science into the new 
batteries using only human cells including reporter cell lines 
derived from induced pluripotent stem cells. Another common 
interest of all initiatives is the extrapolation of in vitro effects 
to the in vivo context. In summary, the research programs are 
highly complementary: Knowledge about toxicity pathways 
from Tox21 and ToxCast inspires the construction of mode-of-
action descriptions in SEURAT-1, and new assays developed 
within SEURAT-1 may find their way into Tox21 and ToxCast. 
Strategies for implementing these tools into safety assessment 
approaches were discussed above (see Section 4) and all ini-
tiatives are well aware that combining their efforts is mutually 
beneficial to all the parties involved. Exchange activities were 
commenced during an expert meeting held at the Joint Research 
Centre in Ispra (Italy) in June 2013. 
5.2  On track? The roadmap and SEURAT-1
Developing new strategies for toxicity testing inevitably re-
quires alignment of different areas of science such as chemis-
try, systems biology, computer sciences and toxicology. The 
SEURAT-1 research initiative assembles the available resources 
in a mode-of-action driven case study approach. This was in-
Tab. 1: Comparison of recommendations from the roadmap for the development of non-animal test methods for the 
replacement of in vivo repeated dose toxicity testing (Basketter et al., 2012) and approaches within SEURAT-1
Recommendations (Basketter et al., 2012)
Joint task force: toxicity database to gather all current data on  
a wide variety of compounds
tiered testing systems and decision trees (ItS) 
 
 
Understand signalling pathways:  
(i) As long as not all pathways of toxicity are known, complex 
systems addressing more apical endpoints should be used too. 
(ii) Use modern tools (e.g., RNAi) for pathway elucidation. 
 
Considerations for the development and validation of in vitro 
systems: 
(i) (Functional) limitations of in vitro systems 
(ii) In the near future, focus on 3D-systems and co-cultures. 
(iii) Selection of appropriate endpoints for each test and test 
system, or “-omics” readouts for many endpoints 
(iv) Measure free concentrations in in vitro systems as a 
prerequisite for quantitative in vitro to in vivo extrapolation. 
(v) Compound selection must consider positive and negative 
controls for the evaluation of the test systems. Consider 
applicability domain, different chemical classes and modes-
of-action. Create a list of reference compounds with available 
information on mechanisms of toxicity and potency 
 
Considerations for the development and validation of in silico 
models: Data quality
SEURAT-1 approaches
Generation of a curated database for cosmetics (COSMOS); 
Collection of SeURAt-1 data in a data warehouse (toxBank)
establishment of integrated testing strategies for toxicity 
prediction based on selected modes-of-action; 
Development of safety assessment strategies based on 
integrated data from non-animal methods
(i) SeURAt-1 will establish high-throughput assays for well-
known pathways of toxicity (SCR&tox) as well as complex 
bioreactors with diverse compositions of cell-types (allowing 
cell-cell interactions; HeMiBio). 
(ii) A battery of omics technologies are being used for pathway 
identification in DETECTIVE and NOTOX.
(i) targeted development of test systems (according to the 
selected modes-of-action), full characterisation of biological 
models used in the test systems 
(ii) emphasis on organotypic cell cultures in NOtOx and 
HeMiBio 
(iii) Development of test systems according to pre-defined 
prediction goals. endpoints: Functional readouts and “-omics” 
(SCR&tox, HeMiBio, DeteCtIVe, NOtOx) 
(iv) Activities within COSMOS and in the cross-cluster 
biokinetics working group  
(v) Selection of reference compounds at the beginning of 
the project by a cross-cluster working group led by toxBank. 
Information on mechanisms of toxicity and potency collected 
and now publicly available as a wiki (http://wiki.toxbank.net/
wiki/)
Activities in the cross-cluster working group on integrated data 
analysis led by ToxBank. Definition of standards for quality 
control / quality assurance for data compilation in the toxBank 
data warehouse (annotation of respective measures as part of 
the data upload procedure).
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“paradigm.” Providing such a blueprint is challenging, but im-
plementing a new strategy into regulation with the intention of 
changing the traditional safety assessment paradigm is probably 
even more challenging. Incorporating scientific advancements 
into current regulation is never an easy task. However, a para-
digm shift in the redefinition of adversity, moving away from 
descriptive toxicology towards mechanism-based predictive 
toxicology, will fail if the regulatory bodies do not recognize the 
concepts emerging from these scientific efforts. It would sim-
ply remain theory without consequences and societal impact. 
There is no doubt that the implementation of a new safety as-
sessment paradigm is a joint undertaking between scientists and 
regulators. Therefore, communication and the bridging of gaps 
between these two communities are of utmost importance. Sci-
entists should listen to the requirements of the regulators, and 
regulators should pay attention to opportunities emerging from 
progressing science. In essence, future research consortia in this 
field, whether it is a SEURAT-1 follow-up or another program, 
should effectively combine these two communities. This is in 
the interest of a sustainable, successful implementation of a new 
safety assessment paradigm. We are just at the beginning, but 
are not absolute beginners...
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